The Pharmaceutical Benefits Advisory Committee is set to recommend the addition of RU486 to the Pharmaceutical Benefits Scheme today, and the medical abortion drug is likely to get the go-ahead from Health Minister Tanya Plibersek.

But listing on the PBS isn't automatic -- the net cost implications to taxpayers of listing additional drugs are subject to vetting by the Department of Finance, and major new additions need cabinet approval.